Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
NRBO | US
0.20
6.76%
Healthcare
Biotechnology
30/06/2024
17/10/2024
3.16
2.88
3.27
2.88
NeuroBo Pharmaceuticals Inc. a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241 a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726 a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity. The company also develops ANA001 a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Boston Massachusetts.
View LessStrength based on increasing price with high volume
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
103.1%1 month
84.4%3 months
77.9%6 months
71.7%-
-
1.15
0.01
0.01
-0.43
-
-
-26.51M
26.82M
26.82M
-
-
-
-
-117.36
0.57
1.05
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
1.19
Range1M
1.64
Range3M
2.73
Rel. volume
1.76
Price X volume
354.44K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Marker Therapeutics Inc | MRKR | Biotechnology | 3.25 | 29.00M | -7.67% | n/a | 0.00% |
ImmuCell Corporation | ICCC | Biotechnology | 3.625 | 28.39M | 1.83% | n/a | 67.52% |
Kala Pharmaceuticals Inc | KALA | Biotechnology | 5.1119 | 28.02M | -2.82% | n/a | 268.29% |
Mawson Infrastructure Group Inc. Common Stock | MIGI | Biotechnology | 1.45 | 26.90M | -0.68% | n/a | 571.64% |
Akari Therapeutics Plc | AKTX | Biotechnology | 2.21 | 26.84M | -12.30% | n/a | -27.01% |
PLUR | PLUR | Biotechnology | 4.8089 | 26.31M | -2.85% | n/a | 30845.83% |
SABS | SABS | Biotechnology | 2.76 | 25.47M | -11.25% | n/a | 11.58% |
Tonix Pharmaceuticals Holding Corp | TNXP | Biotechnology | 0.1794 | 25.11M | 12.83% | n/a | 21.99% |
Iterum Therapeutics plc | ITRM | Biotechnology | 1.09 | 24.75M | 5.83% | n/a | -198.11% |
iBio Inc | IBIO | Biotechnology | 2.85 | 24.62M | 0.00% | n/a | 20.92% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 12.6 | 19.19M | 0.80% | n/a | 204.46% |
ILAG | ILAG | Building Products & Equipment | 0.98 | 17.70M | -3.92% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5763 | 8.36M | -11.91% | 0.04 | 16.03% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2111 | 3.79M | 2.93% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.04 | 2.71M | -4.59% | n/a | 9.62% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0114 | 1.02M | 14.00% | n/a | -37.05% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 60.16 | 0 | -0.43% | n/a | |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 4.3 | 0 | 2.14% | n/a | |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.535 | 0 | 7.00% | n/a | |
Urban One Inc | UONEK | Broadcasting - Radio | 1.07 | 0 | 1.90% | n/a |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -0.43 | 0.53 | Cheaper |
Ent. to Revenue | - | 4,005.99 | - |
PE Ratio | - | 40.42 | - |
Price to Book | 1.15 | 15.30 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 77.89 | 72.92 | Par |
Debt to Equity | 0.01 | -1.24 | Expensive |
Debt to Assets | 0.01 | 0.25 | Cheaper |
Market Cap | 26.82M | 3.78B | Emerging |